-- As part of a panel discussion on bipolar disorder, actress Debi Mazar revealed today that her family has been affected firsthand by this disease. Mazar, best known for her recent performances on "Dancing with the Stars" and the HBO hit series "Entourage," talked about the impact bipolar depression has had on her family ever since a close relative was diagnosed with the disease 10 years ago.

Three Saudi soldiers were killed and several others wounded in their fight against Yemeni rebels at border areas, Asharq al-Awsat daily reported Sunday.

Nov. 19--AstraZeneca could face as many as 6000 lawsuits after a judge in America ruled that claims against its psychiatric treatment Seroquel should be put on trial separately.

19 November 2009 - UK-based pharmaceutical company AstraZeneca plc today announced it has submitted a New Drug Application to the US Food and Drug Administration for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome. The proposed trade name for ticagrelor is BRILINTA, pending approval from the FDA.

19 November 2009 - Anglo-Swedish pharma major AstraZeneca said today it has applied for marketing approval of its experimental blood thinner ticagrelor, or Brilinta, in the USA. The drug, which if approved by the US Food and Drug Administration will be sold under the brand Brilinta, is an investigational oral anti-platelet treatment of acute coronary syndrome.

19 November 2009 - Anglo-Swedish pharma major AstraZeneca said today it has applied for marketing approval of its experimental blood thinner ticagrelor, or Brilinta, in the USA. The drug, which if approved by the US Food and Drug Administration will be sold under the brand Brilinta, is an investigational oral anti-platelet treatment of acute coronary syndrome.

19 November 2009 - Anglo-Swedish pharma major AstraZeneca said today it has applied for marketing approval of its experimental blood thinner ticagrelor, or Brilinta, in the USA. The drug, which if approved by the US Food and Drug Administration will be sold under the brand Brilinta, is an investigational oral anti-platelet treatment of acute coronary syndrome.

Anglo-Swedish pharmaceutical company AstraZeneca reported on Thursday the submission of a New Drug Application to the US Food and Drug Administration for ticagrelor. The product is an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome.

Anglo-Swedish pharmaceutical company AstraZeneca reported on Thursday the submission of a New Drug Application to the US Food and Drug Administration for ticagrelor. The product is an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome.

16 November 2009 - Anglo-Swedish pharma major AstraZeneca announced yesterday the results of a sub-analysis of its PLATO study, showing that treatment with its experimental blood thinner ticagrelor versus clopidogrel led to a reduction of cardiovascular events without an increase in major bleeding. The results were presented at the American Heart Association Scientific Sessions.